Pre-Made hACE2 AAV Vectors – Coronavirus

Add to cart

Traditional knock-in animal models for coronavirus research are time-consuming, labor-intensive, and resource-demanding. Our pre-made hACE2 AAV vectors offer a rapid and efficient solution to accelerate your research. It is a powerful tool for modeling coronavirus infection and evaluating potential therapeutic interventions. By delivering the human ACE2 (hACE2) receptor gene to specific tissues, these vectors enable the study of viral entry, replication, and pathogenesis.

Advantages of Packgene’s AAV-hACE2 Animal Models:

Rapid Model Generation: Significantly faster than traditional knock-in models.
Tissue-Specific Expression: Target specific tissues, such as the lung, for accurate modeling.
Stable and Long-Term Expression: Consistent hACE2 expression over time.
Reduced Animal Numbers: Fewer animals required for experiments, improving efficiency and reducing costs.

Comparison between AAV-hACE2 animal modeling and traditional animal modeling:

	AAV-hACE2 animal modeling	Traditional animal modeling
Production Cycle	Short cycle within 14 days	Over 6 months
Process	Simple	Complicated steps
Histotropism	Specific distribution	Wide distribution

Key Benefits of Our AAV-hACE2 Vectors:

Efficient hACE2 Expression: High-level expression of hACE2 in target tissues.
High-Quality Production: Rigorously tested and quality-controlled to ensure optimal performance.
Ready-to-Use: Our pre-made vectors are designed for immediate use, saving you time and effort.

Premade hACE2 AAV

Promoter type	Catalog No.	Promoter and Gene	AAV type
Universal promoter	AAV-C-1875	ssAAV.CAG.human ACE2.WPRE.SV40pA	ssAAV

Applications:

Virus Entry and Replication Studies: Investigate the mechanisms of viral entry and replication.
Drug Discovery and Development: Screen for antiviral drugs and vaccines.
Pathogenesis Studies: Understand the underlying mechanisms of disease progression.

Contact Us

Case Study

Products: AAVrh10 from PackGene Biotech
Injection Method: Intranasal Administration
Recommended Dose: 2×10^11GC/ml, 40μl
Animal Model: 6-8-week-old female BALB/c mice
Journal: Antiviral Research, 2022 (IF=10.103)
Paper Title: Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants
DOI: https://doi.org/10.1016/j.antiviral.2022.105383

AAVrh10 expressing the different ACE2 fragments, including shACE2, shACE2PD, shACE2(PD + Neck), hACE224-83, dACE224-83, were packaged by PackGene Biotech.

Publications

H. Yang, J.-N. Zhou, X.-M. Zhang, D.-D. Ling, Y.-B. Sun, C.-Y. Li, Q.-Q. Zhou, G.-N. Shi, S.-H. Wang, X.-S. Lin, T. Fan, H.-Y. Wang, Q. Zeng, Y.-L. Jia, J.-F. Xi, Y.-G. Jin, X.-T. Pei, W. Yue, Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS-CoV-2 Pseudovirus Entry into Lung ACE2⁺Cells. Adv. Mater. 2024, 36, 2310306. https://doi.org/10.1002/adma.202310306

Hu, X., Wang, S., Fu, S. et al. Intranasal mask for protecting the respiratory tract against viral aerosols. Nat Commun 14, 8398 (2023). https://doi.org/10.1038/s41467-023-44134-w

Wang, J., Deng, C., Liu, M. et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat Commun 13, 6866 (2022). https://doi.org/10.1038/s41467-022-34633-7